Signal Genetics Adds Precision Therapeutics to Suit | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics has filed an amended lawsuit against Med BioGene, adding Precision Therapeutics as a defendant in a case it brought earlier this month to the Supreme Court for the County of New York.

Signal has accused Vancouver, British Columbia-based Med BioGene with fraud and Pittsburgh-based Precision Therapeutics with tortious interference in the amended complaint filed yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.